| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| References | |
|---|---|
| Additional Infomation |
3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one is an aromatic ketone.
Benperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others. A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567) |
| Molecular Formula |
C22H24FN3O2
|
|---|---|
| Molecular Weight |
381.4514
|
| Exact Mass |
381.185
|
| CAS # |
2062-84-2
|
| Related CAS # |
Benperidol-d4
|
| PubChem CID |
16363
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Vapour Pressure |
7.96E-17mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
4.09
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
556
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)N=C(N2C3CCN(CCCC(=O)C4=CC=C(C=C4)F)CC3)O
|
| InChi Key |
FEBOTPHFXYHVPL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)
|
| Chemical Name |
3-[1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl]-1H-benzimidazol-2-one
|
| Synonyms |
Anquil McN-JR-4584Benperidol R 4584 R4584R-4584 McN JR 4584 McNJR4584
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~262.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6216 mL | 13.1079 mL | 26.2158 mL | |
| 5 mM | 0.5243 mL | 2.6216 mL | 5.2432 mL | |
| 10 mM | 0.2622 mL | 1.3108 mL | 2.6216 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02307396 | COMPLETED | Drug: Olanzapine Drug: Amisulpride Drug: Risperidone |
Schizoaffective Disorders Schizophrenia Schizophrenia and Disorders With Psychotic Features |
Technical University of Munich | 2015-02-01 | Phase 4 |
| NCT02435095 | TERMINATED | Drug: Maintenance treatment Drug: Intermittent treatment |
Schizophrenia | RWTH Aachen University | 2015-05 | Phase 4 |
| NCT01323205 | COMPLETED | Drug: JNJ-40411813 Drug: JNJ-40411813 Drug: Placebo Drug: Antipsychotic medication |
Schizophrenia | Janssen Research & Development, LLC | 2011-05 | Phase 2 |
| NCT02374567 | TERMINATED | Drug: Phenobarbital Drug: Phenytoin Drug: Carbamazepine |
Anxiety Disorders Dementia Depression Psychosomatic Disorders Schizophrenia |
Hannover Medical School | 2015-01 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
